Laminin-5-enriched extracellular matrix accelerates angiogenesis and neovascularization in association with ePTFE

Journal of Biomedical Materials Research - Part A

Volumn 69, Issue 2, 2004, Pages 294-304

  Kidd, Kameha R ^a   Williams, Stuart K ^a  

^a University of Arizona   (United States)

Author keywords

Angiogenesis; EPTFE; Extracellular matrix; Laminin 5

Indexed keywords

ANGIOGRAPHY; BIOMEDICAL EQUIPMENT; BLOOD VESSELS; COLLAGEN; POLYTETRAFLUOROETHYLENES; TISSUE;

EXTRACELLULAR MATRIX MODIFICATION; HEALING RESPONSE;

BIOMATERIALS;

COLLAGEN; FIBRONECTIN; KALININ; LAMININ; MATRIGEL; POLITEF; POLYMER;

ADIPOSE TISSUE; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIOMEDICAL ENGINEERING; CELL LINE; DEVICE; ENDOTHELIUM CELL; EPITHELIUM CELL; EXTRACELLULAR MATRIX; HISTOLOGY; HUMAN; HUMAN CELL; IMPLANT; MACROPHAGE; MEDICAL INSTRUMENTATION; MONOCYTE; MORPHOMETRICS; NONHUMAN; PERFORMANCE; RAT; SUBCUTANEOUS TISSUE; TREATMENT FAILURE; VASCULARIZATION;

EID: 1842730221     PISSN: 00219304     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbm.a.20133     Document Type: Article

References (61)

1. Didisheim P. An approach to biocompatibility. Cardiovasc Pathol 1993;2:1S-2S.
2. Sharkawy AA, Klitzman B, Truskey GA, Reichert WM. Engineering the tissue which encapsulates subcutaneous implants. I. Diffusion properties. J Biomed Mater Res 1997;37:401-412.
3. Sanders JE, Stiles CE, Hayes CL. Tissue response to single-polymer fibers of varying diameters: evaluation of fibrous encapsulation and macrophage density. J Biomed Mater Res 2000;52:231-237.
4. Gerritsen M. Problems associated with subcutaneously implanted glucose sensors. Diabetes Care 2000;23:143-145.
5. Sharkawy AA, Klitzman B, Truskey GA, Reichert WM. Engineering the tissue which encapsulates subcutaneous implants. II. Plasma-tissue exchange properties. J Biomed Mater Res 1998;40:586-597.
6. Updike SJ, Shults MC, Gilligan BJ, Rhodes RK. A subcutaneous glucose sensor with improved longevity, dynamic range, and stability of calibration. Diabetes Care 2000;23:208-214.
7. Marois Y, Cadi R, Gourdon J, Fatouraee N, King MW, Zhang Z, Guidoin R. Biostability, inflammatory response, and healing characteristics of a fluoropassivated polyester-knit mesh in the repair of experimental abdominal hernias. Artif Organs 2000; 24:533-543.
8. Volder JG, Kolff WJ. Induced growth of connective tissue in cardiovascular prosthesis. Trans Am Soc Artif Intern Organs 1974;20B:521-526.
9. Wesolowski SA, Fries CC, Karlson KE, De Bakey M, Sawyer PN. Porosity: primary determinant of ultimate fate of synthetic vascular grafts. Surgery 1961;50:91-96.
10. Tassiopoulos AK, Greisler HP. Angiogenic mechanisms of endothelialization of cardiovascular implants: a review of recent investigative strategies. J Biomater Sci Polym Ed 2000;11:1275-1284.
11. Greisler HP, Klosak JJ, Dennis JW, Karesh SM, Ellinger J, Kim DU. Biomaterial pretreatment with ECGF to augment endothelial cell proliferation. J Vasc Surg 1987;5:393-399.
12. Greisler HP, Cziperle DJ, Kim DU, Garfield JD, Petsikas D, Murchan PM, Applegren EO, Drohan W, Burgess WH. Enhanced endothelialization of expanded polytetrafluoroethylene grafts by fibroblast growth factor type 1 pretreatment. Surgery 1992;112:244-254.
13. Merzkirch C, Davies N, Zilla P. Engineering of vascular in-growth matrices: are protein domains an alternative to peptides? Anat Rec 2001;263:379-387.
14. Vohra R, Thomson GJ, Carr HM, Sharma H, Walker MG. Comparison of different vascular prostheses and matrices in relation to endothelial seeding. Br J Surg 1991;78:417-420.
15. Koveker GB, Graham LM, Burkel WE, Sell R, Wakefield TW, Dietrich K, Stanley JC. Extracellular matrix preparation of expanded polytetrafluoroethylene grafts seeded with endothelial cells: influence on early platelet deposition, cellular growth, and luminal prostacyclin release. Surgery 1991;109:313-319.
16. Ingber DE, Folkman J. How does extracellular matrix control capillary morphogenesis? Cell 1989;58:803-805.
17. Chen CS, Mrksich M, Huang S, Whitesides GM, Ingber DE. Geometric control of cell life and death. Science 1997;276:1425-1428.
18. Dike LE, Chen CS, Mrksich M, Tien J, Whitesides GM, Ingber DE. Geometric control of switching between growth, apoptosis, and differentiation during angiogenesis using micropatterned substrates. In Vitro Cell Dev Biol Anim 1999;35:441-448.
19. Davis GE, Camarillo CW. Regulation of endothelial cell morphogenesis by integrins, mechanical forces, and matrix guidance pathways. Exp Cell Res 1995;216:113-123.
20. Rongish BJ, Hinchman G, Doty MK, Baldwin HS, Tomanek RJ. Relationship of the extracellular matrix to coronary neovascularization during development. J Mol Cell Cardiol 1996;28: 2203-2215.
21. Kidd KR, Nagle RB, Williams SK. Angiogenesis and neovascularization associated with extracellular matrix-modified porous implants. J Biomed Mater Res 2002;2:366-377.
22. Williams SK, Wang TF, Castrillo R, Jarrell BE. Liposuction-derived human fat used for vascular graft sodding contains endothelial cells and not mesothelial cells as the major cell type. J Vasc Surg 1994;19:916-923.
23. Williams SK, Schneider T, Kapelan B, Jarrell BE. Formation of a functional endothelium on vascular grafts. J Electron Microsc Tech 1991;19:439-451.
24. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970;227:680-685.
25. Williams SK, Berman SS, Kleinert LB. Differential healing and neovascularization of ePTFE implants in subcutaneous versus adipose tissue. J Biomed Mater Res 1997;35:473-481.
26. Ratner BD. New ideas in biomaterials science - a path to engineered biomaterials. J Biomed Mater Res 1993;27:837-850.
27. Greenhalgh RM. Vascular grafts in the 1990s: lessons from the past. Acta Chir Scand 1990;555(Suppl):249-253.
28. Black MM. Cardiovascular applications of biomaterials and implants - an overview. J Med Eng Tech 1995;19:151-157.
29. Hunt JA, McLaughlin PJ, Flanagan BF. Techniques to investigate cellular and molecular interactions in the host response to implanted biomaterials. Biomaterials 1997;18:1449-1459.
30. Ratner BD, Johnston AB, Lenk TJ. Biomaterial surfaces. J Biomed Mater Res 1987;21:59-89.
31. Shireman PK, Greisler HP. Mitogenicity and release of vascular endothelial growth factor with and without heparin from fibrin glue. J Vasc Surg 2000;31:936-943.
32. Lindner V, Majack RA, Reidy MA. Basic fibroblast growth factor stimulates endothelial regrowth and proliferation in denuded arteries. J Clin Invest 1990;85:2004-2008.
33. Wissink MJ, Beernink R, Poot AA, Engbers GH, Beugeling T, van Aken WG, Feijen J. Improved endothelialization of vascular grafts by local release of growth factor from heparinized collagen matrices. J Control Release 2000;64:103-114.
34. De Vos P, Hillebrands JL, De Haan BJ, Strubbe JH, Van Schilfgaarde R. Efficacy of a prevascularized expanded polytetrafluoroethylene solid support system as a transplantation site for pancreatic islets. Transplantation 1997;63:824-830.
35. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000;6:389-395.
36. Pepper MS, Mandriota SJ, Vassalli JD, Orci L, Montesano R. Angiogenesis-regulating cytokines: activities and interactions. Curr Top Microbiol Immunol 1996;213:31-67.
37. Pepper MS. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler Thromb Vasc Biol 2001;21:1104-1117.
38. Wissink MJ, Beernink R, Scharenborg NM, Poot AA, Engbers GH, Beugeling T, van Aken WG, Feijen J. Endothelial cell seeding of (heparinized) collagen matrices: effects of bFGF pre-loading on proliferation (after low density seeding) and pro-coagulant factors. J Control Release 2000;67:141-155.
39. Wissink MJ, van Luyn MJ, Beernink R, Dijk F, Poot AA, Engbers GH, Beugeling T, van Aken WG, Feijen J. Endothelial cell seeding on crosslinked collagen: effects of crosslinking on endothelial cell proliferation and functional parameters. Thromb Haemost 2000;84:325-331.
40. Anderson JM. Inflammatory response to implants. ASAIO Trans 1988;34:101-107.
41. Udipi K, Ornberg RL, Thurmond KB, Settle SL, Forster D, Riley D. Modification of inflammatory response to implanted biomedical materials in vivo by surface bound superoxide dismutase mimics. J Biomed Mater Res 2000;51:549-560.
42. Sunderkotter C, Steinbrink K, Goebeler M, Bhardwaj R, Sorg C. Macrophages and angiogenesis. J Leukoc Biol 1994;55:410-422.
43. Miller KM, Anderson JM. In vitro stimulation of fibroblast activity by factors generated from human monocytes activated by biomedical polymers. J Biomed Mater Res 1989;23:911-930.
44. Kao WJ, Lee D. In vivo modulation of host response and macrophage behavior by polymer networks grafted with fibronectin-derived biomimetic oligopeptides: the role of RGD and PHSRN domains. Biomaterials 2001;22:2901-2909.
45. Brauker JH, Carr-Brendel VE, Martinson LA, Crudele J, Johnston WD, Johnson RC. Neovascularization of synthetic membranes directed by membrane microarchitecture. J Biomed Mater Res 1995;29:1517-1524.
46. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-364.
47. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992;267:10931-10934.
48. Giordano FJ, Johnson RS. Angiogenesis: the role of the micro-environment in flipping the switch. Curr Opin Genet Dev 2001;11:35-40.
49. Passaniti A, Taylor RM, Pili R, Guo Y, Long PV, Haney JA, Pauly RR, Grant DS, Martin GR. A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab Invest 1992;67:519-528.
50. Garrido T, Riese HH, Aracil M, Perez-Aranda A. Endothelial cell differentiation into capillary-like structures in response to tumour cell conditioned medium: a modified chemotaxis chamber assay. Br J Cancer 1995;71:770-775.
51. Kikkawa Y, Sanzen N, Sekiguchi K. Isolation and characterization of laminin-10/11 secreted by human lung carcinoma cells. laminin-10/11 mediates cell adhesion through integrin alpha3 beta1. J Biol Chem 1998;273:15854-15859.
52. Kikkawa Y, Sanzen N, Fujiwara H, Sonnenberg A, Sekiguchi K. Integrin binding specificity of laminin-10/11: laminin-10/11 are recognized by alpha 3 beta 1, alpha 6 beta 1 and alpha 6 beta 4 integrins. J Cell Sci 2000;113:869-876.
53. Kortesmaa J, Yurchenco P, Tryggvason K. Recombinant laminin-8 (alpha(4)beta(1)gamma(1)). Production, purification, and interactions with integrins. J Biol Chem 2000;275: 14853-14859.
54. Wagner S, Tagaya M, Koziol JA, Quaranta V, del Zoppo GJ. Rapid disruption of an astrocyte interaction with the extracellular matrix mediated by integrin alpha 6 beta 4 during focal cerebral ischemia/reperfusion. Stroke 1997;28:858-865.
55. Wagner S, Gardner H. Modes of regulation of laminin-5 production by rat astrocytes. Neurosci Lett 2000;284:105-108.
56. Kikkawa Y, Akaogi K, Mizushima H, Yamanaka N, Umeda M, Miyazaki K. Stimulation of endothelial cell migration in culture by ladsin, a laminin-5-like cell adhesion protein. In Vitro Cell Dev Biol Anim 1996;32:46-52.
57. Jones JC, Hopkins SB, Goldfinger LE. Structure and assembly of hemidesmosomes. BioEssays 1999;20:488-494.
58. Homan SM, Mercurio AM, LaFlamme SE. Endothelial cells assemble two distinct α6β4-containing vimentin-associated structures: roles for ligand binding and the β4 cytoplasmic tail. J Cell Sci 1998;111:2717-2728.
59. Fujiwara H, Kikkawa Y, Sanzen N, Sekiguchi K. Purification and characterization of human laminin-8. Laminin-8 stimulates cell adhesion and migration through alpha3beta1 and alpha6beta1 integrins. J Biol Chem 2001;276:17550-17558.
60. Klein S, Giancotti FG, Presta M, Albelda SM, Buck CA, Rifkin DB. Basic fibroblast growth factor modulates integrin expression in microvascular endothelial cells. Mol Biol Cell 1993;4: 973-982.
61. Kleinman HK, McGarvey ML, Liotta LA, Robey PG, Tryggvason K, Martin GR. Isolation and characterization of type IV procollagen, laminin, and heparan sulfate proteoglycan from the EHS sarcoma. Biochemistry 1982;21:6188-6193.